Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) has received an average recommendation of “Hold” from the fourteen brokerages that are presently covering the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $6.24.

Several analysts have recently weighed in on KERX shares. Zacks Investment Research lowered shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 26th. JMP Securities restated an “outperform” rating on shares of Keryx Biopharmaceuticals in a research report on Thursday, September 8th. Vetr upgraded shares of Keryx Biopharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $5.93 price target on the stock in a research report on Wednesday, October 12th. Raymond James Financial Inc. boosted their price target on shares of Keryx Biopharmaceuticals from $7.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, August 2nd. Finally, Maxim Group lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 1st.

Large investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its stake in Keryx Biopharmaceuticals by 5.4% in the second quarter. Parametric Portfolio Associates LLC now owns 25,951 shares of the biopharmaceutical company’s stock worth $172,000 after buying an additional 1,328 shares during the period. California State Teachers Retirement System increased its stake in Keryx Biopharmaceuticals by 0.9% in the third quarter. California State Teachers Retirement System now owns 167,058 shares of the biopharmaceutical company’s stock worth $887,000 after buying an additional 1,500 shares during the period. BlackRock Group LTD increased its stake in Keryx Biopharmaceuticals by 5.0% in the third quarter. BlackRock Group LTD now owns 49,808 shares of the biopharmaceutical company’s stock worth $263,000 after buying an additional 2,379 shares during the period. BlackRock Advisors LLC increased its stake in Keryx Biopharmaceuticals by 5.6% in the third quarter. BlackRock Advisors LLC now owns 45,653 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 2,413 shares during the period. Finally, Marco Investment Management LLC increased its stake in Keryx Biopharmaceuticals by 6.5% in the third quarter. Marco Investment Management LLC now owns 49,350 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 3,000 shares during the period. 62.15% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2016/11/28/analysts-set-keryx-biopharmaceuticals-inc-kerx-price-target-at-6-24.html.

Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 6.23 on Friday. The company’s market capitalization is $660.13 million. Keryx Biopharmaceuticals has a one year low of $2.80 and a one year high of $7.80. The company’s 50-day moving average is $5.21 and its 200-day moving average is $5.49.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.19. Keryx Biopharmaceuticals had a negative net margin of 584.76% and a negative return on equity of 270.26%. The business had revenue of $6.30 million for the quarter, compared to analyst estimates of $5.53 million. During the same quarter last year, the firm posted ($0.29) earnings per share. Keryx Biopharmaceuticals’s revenue was up 50.0% on a year-over-year basis. Equities analysts predict that Keryx Biopharmaceuticals will post ($1.41) earnings per share for the current year.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

5 Day Chart for NASDAQ:KERX

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.